Skip to main content

Drug Interactions between Akeega and deuruxolitinib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

abiraterone deuruxolitinib

Applies to: Akeega (abiraterone / niraparib) and deuruxolitinib

Consumer information for this interaction is not currently available.

CONTRAINDICATED: Concomitant administration with moderate or potent inhibitors of CYP450 2C9 may increase the plasma concentrations of deuruxolitinib, which is primarily metabolized via this isoenzyme. A model-informed approach predicted that coadministration with multiple doses of a potent CYP450 2C9 inhibitor with a single 12 mg dose of deuruxolitinib (1.5 times the approved 8 mg dose) would increase deuruxolitinib systemic exposure (AUC) by 200% and peak plasma concentration (Cmax) by 25%. Similarly, coadministration of deuruxolitinib (12 mg) with multiple doses of fluconazole 200 mg, a dual moderate CYP450 3A4 and CYP450 2C9 inhibitor, increased deuruxolitinib's AUC and Cmax by 140% and 21%, respectively. Additionally, individuals who are poor metabolizers of CYP450 2C9 are expected to have higher exposure of deuruxolitinib, which may increase the risk serious adverse reactions such as thrombosis. Based on drug-drug interaction modeling data, CYP450 2C9 poor metabolizers may have up to 2-fold higher concentration of deuruxolitinib, when compared to normal metabolizers. Pharmacokinetic data of deuruxolitinib for individuals who are intermediate metabolizers have not been evaluated.

MANAGEMENT: Concomitant use of deuruxolitinib with moderate or potent inhibitors of CYP450 2C9 is considered contraindicated.

Drug and food/lifestyle interactions

Moderate

abiraterone food/lifestyle

Applies to: Akeega (abiraterone / niraparib)

This interaction does not apply to abiraterone acetate (Yonsa) 125 mg tablets, which can be taken with or without food.

Taking abiraterone with food increases the amount of medicine that gets absorbed by the body for certain formulations. This may increase the risk of side effects such as high blood pressure, water retention, and a condition called hypokalemia (low blood potassium), which in severe cases can lead to muscle weakness, paralysis, breathing and swallowing difficulties (due to muscle paralysis), and irregular heart rhythm. You should take abiraterone once a day on an empty stomach. No food should be eaten for at least two hours before and one hour after taking abiraterone. Let your doctor know if you experience nausea, vomiting, constipation, abdominal cramping, confusion, dizziness, lightheadedness, fainting, muscle weakness, muscle cramps, numbness or tingling, rapid heartbeat, chest pain, and/or swelling in the legs or feet, as these may be symptoms of hypokalemia or excessive effects of abiraterone. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Moderate

deuruxolitinib food/lifestyle

Applies to: deuruxolitinib

Consumer information for this interaction is not currently available.

MONITOR: Smoking during treatment with deuruxolitinib may increase the risk of major adverse cardiovascular events (MACE) and the risk of developing malignancies. In clinical studies of deuruxolitinib, individuals who were current or former smokers had an additional increased risk of overall malignancies. Also, deuruxolitinib may increase patients' risk of MACE, including myocardial infarction, stroke, and cardiovascular death.

MANAGEMENT: Caution is advised if deuruxolitinib is prescribed to current or past smokers. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. The manufacturer recommends discontinuing deuruxolitinib in patients that have experienced a myocardial infarction or stroke. Deuruxolitinib may be taken with or without food.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer